| Literature DB >> 27639108 |
P A De Sousa1, J M Downie2, B J Tye2, K Bruce2, P Dand2, S Dhanjal3, P Serhal4, J Harper3, M Turner5, M Bateman2.
Abstract
From 2006 to 2011, Roslin Cells Ltd derived 17 human embryonic stem cells (hESC) while developing (RCM1, RC-2 to -8, -10) and implementing (RC-9, -11 to -17) quality assured standards of operation in a facility operating in compliance with European Union (EU) directives and United Kingdom (UK) licensure for procurement, processing and storage of human cells as source material for clinical application, and targeted to comply with an EU Good Manufacturing Practice specification. Here we describe the evolution and specification of the facility, its operation and outputs, complementing hESC resource details communicated in Stem Cell Research Lab Resources.Entities:
Mesh：
Year: 2016 PMID： 27639108 DOI： 10.1016/j.scr.2016.08.011
Source DB: PubMed Journal: Stem Cell Res ISSN： 1873-5061 Impact factor: 2.020